Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Egetis' Emcitate Approved As Treatment For Mct8 Deficiency

    Picture of Egetis Therapeutics AB (publ) logoEgetis Therapeutics AB (publ)
    13/02/2025 14:25
    Feb 13 (Reuters) - Egetis Therapeutics AB (publ)
 EGTX.ST :
    * EUROPEAN COMMISSION APPROVES EGETIS’ EMCITATE®
(TIRATRICOL) AS
THE FIRST AND ONLY TREATMENT FOR PATIENTS WITH MCT8 DEFICIENCY
    * EXPECTS FIRST LAUNCH IN Q2 OF 2025
    * LOOKS FORWARD TO INITIATING PRICING, REIMBURSEMENT
PROCESSES

Source text:  ID:nMFN2L0pDN 
Further company coverage:  EGTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Egetis Therapeutics AB (publ)

    See all news